BACKGROUND Troponins may be elevated in patients with pneumonia, but associations with myocardial infarction (MI)
hospitalization for pneumonia, heart disease, cerebrovascular disease, and the risk for death from all causes during influenza seasons in elderly patients (3) .
A prospective study (4) showing that acetylsalicylic acid (ASA), which inhibits platelet thromboxane A 2 production via irreversible acetylation of COX-1 (6), lowers cardiovascular events in patients with acute or chronic coronary heart disease (CHD) (7) . In patients with pneumonia or other infections, previous studies showed in vivo elevation of platelet activation biomarkers, suggesting potential interplay between platelet overactivation and cardiovascular events during pneumonia. Thus, we speculated that in pneumonia, differences in platelet activation might be detected in patients with and without signs of MI. For this purpose, we performed a prospective study in which the relationships between in vivo markers of platelet activation were analyzed in the early phase of hospitalization of patients affected by CAP. Markers analyzed included plasma levels of soluble CD40 ligand (sCD40L) (8) and soluble Pselectin (sP-selectin) (9) ; serum levels of thromboxane B 2 (TxB 2 ), which reflects maximal platelet formation of thromboxane A 2 (10) (11) (12) ; and serum levels of high-sensitivity cardiac troponin T (hscTnT). ST-segment elevation MI and non-ST-segment elevation MI were defined as previously reported (18) . To better define the relationships between TxB 2 , sCD40L, and sP-selectin levels and cardiovascular events, we grouped these continuous marker mea- For multivariate models, model selection was performed using forward stepwise regression on the basis of the Akaike information criterion.
Variance inflation factors were computed to assess collinearity for each predictor in the final multivariate model, with a variance inflation factor < 2.5 considered safe. The variance inflation factor criterion was satisfied in all reported models, hence there were no collinearity issues.
TxB 2 , sCD40L, and sP-selectin levels evaluated at the end of hospitalization were compared with baseline levels by Wilcoxon rank sum tests.
Only p values <0.05 were regarded as statistically significant. All tests were 2-tailed, and analyses were performed using computer software packages (R version 2.15.2, R Development Core Team, Vienna, Austria).
S a m p l e s i z e . The minimum sample size was computed considering 1) an expected rate of MI of 5% (20) (21) (22) (23) (24) ; 2) a relevant difference in TxB 2 levels to be detected between groups of jdj $ 50 ng/ml; 3) a SD between the groups of 35 ng/ml; and 4) type I error probability of a ¼ 0.05 and power of 1 À b ¼ 0.90.
This resulted in a sample size of 220 patients. The expected event rate and TxB 2 levels were obtained by analyzing data from previous studies (25) .
RESULTS
We recruited 278 patients hospitalized for CAP (173 men, 105 women; mean age 70.0 AE 15.7 years).
Most of the patients had arterial hypertension (68%). Histories of CHD were present in 36% of patients, previous strokes in 12%, T2DM in 24%, COPD in 35%, PAD in 7%, and dyslipidemia in 21%.
Histories of paroxysmal atrial fibrillation were present in 12% of patients, while 16% were affected by chronic (persistent or permanent) atrial fibrillation, and 18% had severe renal failure (i.e., glomerular filtration rate <30 ml/min). Among the entire pop- Table 1 . Patients with hs-cTnT elevation (whether or not they developed MIs) were older and had a higher prevalence of COPD, chronic atrial fibrillation, PAD, renal failure, and T2DM than patients without hs-cTnT elevation.
Baseline plasma levels of sCD40L and sP-selectin, serum TxB 2 , and MPV were significantly higher in patients who developed signs of MI. Furthermore, plasma sP-selectin levels were higher in patients with isolated hs-cTnT but without signs of MI (p < 0.001) ( Table 1) . When ASA users and nonusers were considered separately, both sCD40L and sP-selectin Values are mean AE SD, %, or median (interquartile range).
ASA ¼ acetylsalicylic acid; BMI ¼ body mass index; CAF ¼ chronic (persistent or permanent) atrial fibrillation; CAP ¼ community-acquired pneumonia; CHD ¼ coronary heart disease; COPD ¼ chronic obstructive pulmonary disease; hs-CRP ¼ high-sensitivity C-reactive protein; hs-cTnT ¼ high-sensitivity cardiac troponin T; MI ¼ myocardial infarction; MPV ¼ mean platelet volume; PAD ¼ peripheral artery disease; PAF ¼ paroxysmal atrial fibrillation; PSI ¼ Pneumonia Severity Index; sCD40L ¼ soluble CD40 ligand; sP-selectin ¼ soluble P-selectin; T2DM ¼ type 2 diabetes mellitus; TxB2 ¼ thromboxane B2.
Cangemi et al.
sP-selectin, and TxB 2 quartiles (Figure 2) . The largest number of MIs occurred in the upper quartiles of all 3 variables, corresponding to sCD40L >6.0 ng/ml, sP-selectin >26 ng/ml, and TxB 2 >200 ng/ml.
In univariate analysis, age (p < 0.001), PSI score Other abbreviations as in Figure 1 . Cangemi et al. Platelet Activation and MI in Pneumonia myocardial injury (34 Another important issue raised by this study is the inefficacy of ASA 100 mg/day in completely preventing serum TxB 2 formation in patients with pneumonia, suggesting that this dosage does not fully inhibit COX-1. In other clinical settings, it is becoming evident that because of accelerated platelet turnover, a dose of 100 mg ASA twice daily is more effective than ASA 100 mg/day to fully prevent platelet TxB 2 (36) . We cannot exclude that a similar phenomenon may also occur in pneumonia and that another ASA regimen should therefore be adopted in this clinical setting. However, we cannot exclude that the persistent platelet TxB 2 elevation, despite ASA treatment, observed at baseline, may result from lowered ASA bioavailability or poor compliance (37) .
CONCLUSIONS
We provide evidence that >50% of patients with pneumonia had hs-cTnT elevation, which was isolated or associated with MI in about 11% of cases. 
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Elderly patients are at risk for developing myocardial ischemia and infarction early in the course of CAP.
Elevated platelet activation markers and thromboxane A 2 generation in these patients suggest that platelets play a role in the pathogenesis of these cardiac events.
TRANSLATIONAL OUTLOOK: Future studies should address the safety and efficacy of administering ASA or other antiplatelet drugs to patients presenting with acute CAP.
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